======= MYOZ1 ======= == Gene Information == * **Official Symbol**: MYOZ1 * **Official Name**: myozenin 1 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=58529|58529]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9NP98|Q9NP98]] * **Interactions**: [[https://thebiogrid.org/search.php?search=MYOZ1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MYOZ1|Open PubMed]] * **OMIM**: [[https://omim.org/entry/605603|Open OMIM]] == Function Summary == * **Entrez Summary**: The protein encoded by this gene is primarily expressed in the skeletal muscle, and belongs to the myozenin family. Members of this family function as calcineurin-interacting proteins that help tether calcineurin to the sarcomere of cardiac and skeletal muscle. They play an important role in modulation of calcineurin signaling. [provided by RefSeq, Apr 2012]. * **UniProt Summary**: Myozenins may serve as intracellular binding proteins involved in linking Z-disk proteins such as alpha-actinin, gamma- filamin, TCAP/telethonin, LDB3/ZASP and localizing calcineurin signaling to the sarcomere. Plays an important role in the modulation of calcineurin signaling. May play a role in myofibrillogenesis. |Calsarcin| |negative regulation of skeletal muscle tissue regeneration| |skeletal muscle fiber adaptation| |FATZ binding| |telethonin binding| |regulation of skeletal muscle tissue regeneration| |protein serine/threonine phosphatase inhibitor activity| |skeletal muscle adaptation| |negative regulation of calcineurin-mediated signaling| |negative regulation of calcineurin-NFAT signaling cascade| |pseudopodium| |striated muscle adaptation| |negative regulation of calcium-mediated signaling| |muscle adaptation| |regulation of calcineurin-mediated signaling| |regulation of calcineurin-NFAT signaling cascade| |sarcomere organization| |negative regulation of phosphoprotein phosphatase activity| |negative regulation of protein dephosphorylation| |myofibril assembly| |negative regulation of wound healing| |negative regulation of response to wounding| |regulation of calcium-mediated signaling| |cellular component assembly involved in morphogenesis| |negative regulation of developmental growth| |negative regulation of phosphatase activity| |negative regulation of dephosphorylation| |actomyosin structure organization| |regulation of phosphoprotein phosphatase activity| |skeletal muscle tissue development| |Z disc| |skeletal muscle organ development| |striated muscle cell development| |regulation of wound healing| |regulation of protein dephosphorylation| |muscle cell development| |regulation of response to wounding| |regulation of phosphatase activity| |striated muscle cell differentiation| |regulation of dephosphorylation| |actin cytoskeleton| |negative regulation of growth| |muscle cell differentiation| |actin binding| |striated muscle tissue development| |muscle organ development| |muscle tissue development| |muscle system process| |regulation of developmental growth| |negative regulation of response to external stimulus| |negative regulation of hydrolase activity| |supramolecular fiber organization| |muscle structure development| |actin cytoskeleton organization| |negative regulation of intracellular signal transduction| |negative regulation of phosphate metabolic process| |negative regulation of phosphorus metabolic process| |actin filament-based process| |negative regulation of protein modification process| |regulation of growth| |organelle assembly| |negative regulation of catalytic activity| |cellular component morphogenesis| |negative regulation of transcription by RNA polymerase II| |anatomical structure formation involved in morphogenesis| |negative regulation of developmental process| |negative regulation of cellular protein metabolic process| |regulation of response to external stimulus| |negative regulation of protein metabolic process| |cytoskeleton organization| |negative regulation of molecular function| |negative regulation of transcription, DNA-templated| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of signal transduction| |regulation of hydrolase activity| |negative regulation of RNA metabolic process| |negative regulation of cell communication| |negative regulation of signaling| |negative regulation of cellular macromolecule biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |regulation of response to stress| |negative regulation of cellular biosynthetic process| |negative regulation of biosynthetic process| |negative regulation of response to stimulus| |cell development| |negative regulation of gene expression| |tissue development| |regulation of phosphate metabolic process| |regulation of phosphorus metabolic process| |regulation of intracellular signal transduction| |regulation of protein modification process| |system process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.72| |[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|1.72| |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|1.75| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 3886 * **Expression level (log2 read counts)**: -7.68 {{:chemogenomics:nalm6 dist.png?nolink |}}